ASX Announcements 2010 ASX Announcements 2009 ASX Announcements 2008 ASX Announcements 2007 ASX Announcements 2006 ASX Announcements 2005 ASX Announcements 2004 ASX Announcements 2003 ASX Announcements 2002 Should you wish to view the report in your browser, you will need to have the Acrobat Reader installed. Please click on the icon (right) and follow the instructions. ASX Announcements 2006 ATL1103 to progress towards clinical development 20/12/2006   Appendix 3B 15/11/2006   Section 708A(5)(e) 15/11/2006   Market Developments - Antisense Technology 13/11/2006   Appendix 3B 13/11/2006   Share Placement to Overseas Institutional Investors 13/11/2006   Section 708A(5)(e) Notice 13/11/2006   Change of Director's Interest Notice 03/11/2006   Appendix 4C Quarterly Cashflow Report 24/10/2006   Chairman's Address & Presentation 17/10/2006   Animal study results provide further support for the potential of ATL1102 for Multiple Sclerosis 11/10/2006   Annual General Meeting Results 10/10/2006   ATL1102 Phase IIa MS Trial update 04/10/2006   Seminar by Dr Frank Bennett at Bio21 Institute 03/10/2006   Notice of AGM & Annual Report 08/09/2006   Lead Compound ATL1102 - Patent granted in Japan 29/08/2006   Preliminary Final Report - Appendix 4E 07/08/2006   Appendix 3Z - Final Director's Interest Notice 03/08/2006   Appendix 3X - Initial Director's Interest Notice 03/08/2006   Appendix 4C - Quarterly Cashflow Report 25/07/2006   Retirement & Appointment of Non-Executive Directors 07/07/2006   Market Developments - Tysabri receives approval in European Union for the treatment of relapsing remitting forms of MS 30/06/2006   Audio Broadcast 28/06/2006   Commencement of dosing of patients in Phase IIa MS Trial 21/06/2006   Appointment of New Company Secretary 20/06/2006   Market Developments - FDA approves reintroduction of Tysabri® 07/06/2006   Market Developments-Validation for 2nd Generation Antisense Drug Devlopment 28/04/2006   Appendix 4C - Quarterly Cashflow report 19/04/2006   Appendix 3B - New Share Issue 10/04/2006   Notice under sec 708A(5)(e) of the Corporations Act 2001 10/04/2006   Results of Extraordinary General Meeting 06/04/2006   Company Update 04/04/2006   Market Developments 09/03/2006   Notice of General Meeting 03/03/2006   Share Placement to Institutional & Professional Investors 17/02/2006   Half Year Report 17/02/2006   Appendix 4C - Quarterly Cashflow Report 19/01/2006   Approval to restart Phase IIa trial in MS patients 12/01/2006